CA
NZ
UK
AU
IND
US
Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both delivered second-quarter results that exceeded Wall Street's expectations and prompted both companies to raise their full-year outlooks, yet the market's reaction could not have been more different. Lilly shares rose on the day of its report, …
Amazon's (NASDAQ:AMZN) pharmacy unit said it will offer weight-loss drugs to eligible Medicare beneficiaries for $50 a month through the Medicare GLP-1 Bridge Program, a federal initiative created to expand access to the treatments. The program, which launched last month and runs through the …
Zai Lab Limited reported total revenues of $106.3 million for the second quarter of 2026, falling short of the $110.0 million seen the previous year and below market expectations. This disappointing performance highlights challenges faced in stabilizing product demand, despite year-over-year product revenue increasing …
Zoetis Inc. (NYSE: ZTS) released its second-quarter results, revealing no growth in revenue, which totalled $2.5 billion, flat compared to the same period last year. The company's adjusted net income increased slightly by 1% to $781 million, reflecting stronger performance on a diluted share …
Teleflex Incorporated (NYSE: TFX) delivered a strong second quarter performance, announcing adjusted earnings per share of $1.76, a substantial improvement over the consensus estimate of $1.29. The company saw its revenue from continuing operations reach $570.3 million, marking a strong 28.9% increase year-over-year. The …
Viatris Inc. reported total revenues of $3.8 billion for the second quarter ended June 30, 2026, marking a solid 5% increase from the previous year. The results surpassed market expectations, with earnings per share at $0.69 compared to a consensus estimate of $0.61. Driven …
Viridian Therapeutics, Inc. achieved an earnings per share (EPS) of $-0.90 for the second quarter of 2026, surpassing the consensus estimate of $-1.12. This marked improvement highlights the company's ongoing efforts to manage costs and optimize operations in its biotechnology focus on autoimmune diseases. …
This marks a significant financial improvement for the company, which previously faced challenges maintaining its market position. Against a sector background where shares of comparable firms like RNAZ fell by 2.1%, VivoSim's compliance aligns with an uptick in confidence among investors, especially after the …
West Pharmaceutical Services Inc. (NYSE: WST) reported second-quarter 2026 revenues of $872.3 million, representing a year-over-year increase of 13.8%. This growth was driven by a 12.7% increase in organic sales. The adjusted-diluted earnings per share (EPS) rose to $2.37, marking a substantial 28.8% increase.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) announced an $87.5 million equity financing on August 6, 2026, which is equivalent to around 42% of its market capitalization of $207 million. This infusion of capital positions the company to continue its Phase 1 clinical trials for its …
Please wait processing your request...